ABOUT CORDIS
Resilient growth in a
defensive sector
Cordis’ origination came from hospital operating theatres, rather than a Wall St trading floor, providing us with inimitable medtech insights which continue to provide our sustainable competitive advantage today.
We have built our circle of competence around investing in the secular tailwinds driving the medical technology industry. We invest in our best ideas for the long-term because we believe we are still in the early stages of a long-term structural trend.
GENESIS OF CORDIS
An equity fund established to harness the secular shift in healthcare treatment.
Or what we like to call the Revolution in Medical Technology.
It was the studied observation of Professor Michael Vallely and Michael Cartmill over many years that the use of sophisticated medical technology for treatment of chronic disease has been steadily climbing. The inflection point in medtech adoption was reached later than the rest of the technology sector due to years of clinical trials and thousands of hours of required operating theatre time. It was during this period that conviction was built up in the safety and efficacy profile of new devices. Importantly, this period also allowed time to build the case that these devices offered overall cost savings to the healthcare system due to significantly reduced surgery times and lower readmission rates. This Revolution in Medical Technology has become the answer to world’s problem with burgeoning healthcare budgets.
The Founders recognised this as one of the most intuitively logical and resilient growth opportunities in the market, underwritten by a universal desire of the world’s ageing population to live a longer and better-quality of life. Pairing the undeniable tailwinds of healthcare demand with the safest, most effective and lowest cost solution, was the genesis of Cordis Asset Management.